EMDPCOS: Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)

Sponsor
St George's, University of London (Other)
Overall Status
Suspended
CT.gov ID
NCT03652987
Collaborator
SPD Development Company Limited (Industry)
300
1
59.9
5

Study Details

Study Description

Brief Summary

Polycystic ovary syndrome (PCOS) is a common endocrine disorder in reproductive age women, which causes disordered follicle growth and ovulation resulting in infertility. In addition women with PCOS have hyperandrogenemia and a dysregulated hormonal profile, resulting in altered feedback on the hypothalamic-pituitary-gonadal (HPG) axis. Obesity, insulin resistance, vitamin D (VD) deficiency and ageing worsen the symptoms. The gonadotrophins - follicle stimulating hormone (FSH) & luteinising hormone (LH), along with the pregnancy hormone human chorionic gonadotrophin (hCG) have structural similarities. The altered levels of FSH and LH in women with PCOS cause production of hCG from the brain leading to false positive pregnancy tests. Part one of this project will involve the investigation of this over-production of hCG in urine and serum of women with PCOS to develop suitable ovulation and pregnancy test kits, in collaboration with Swiss Precision Diagnostics (SPD). In Part two of the project, we would like to see if intervention with VD supplementation and/or using myo-inositol supplement compared with metformin (insulin sensitiser), improves prediabetes, distribution of fat/water content, weight loss and menstrual cyclicity in women with PCOS. We aim to correlate these interventions with particular serum & urine markers to develop better diagnostic tools.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Women are referred by the general practioner (GP)/primary care with a suspected diagnosis of PCOS to the Endocrine Clinic at St George's Hospital.

    They have an initial routine clinical assessment involving history, BP, weight & assessment of PCOS using the Rotterdam criteria.

    The routine clinical investigations involve the following:

    • one fasting blood sample to measure various hormones; fasting glucose:insulin ratio; pelvic ultrasound scan to determine ovarian morphology, follicular count and endometrial thickness

    Part 1 of the research protocol will include obtaining the following:
    • One urine & serum sample to be taken at the same time as their routine clinical blood samples.

    • These samples will be anonymised before despatch to SPD. Part 2 of the study will involve treating patients with Vitamin D (if they are deficient) and/or myo-inositol supplement or metformin depending on their clinical need. The outcomes measured will be as above (blood sample to measure hormones) and an assessment of body fat distribution.

    Study Design

    Study Type:
    Observational [Patient Registry]
    Anticipated Enrollment :
    300 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Evaluation of Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS): Impact of Weight, Metabolic Status, Age and Ethnicity.
    Actual Study Start Date :
    Sep 5, 2018
    Anticipated Primary Completion Date :
    Dec 1, 2022
    Anticipated Study Completion Date :
    Sep 1, 2023

    Outcome Measures

    Primary Outcome Measures

    1. Assay measurements of hormones in blood and urine samples i.e. testosterone, SHBG, FSH, LH, VD, AMH, fasting insulin & glucose. [6 months]

      Statistically significant differences in: levels of hormone/factors produced as measured in blood and urine samples sent to pathology lab; hormonal & metabolic responses/parameters after dietary/pharmaceutical intervention

    Secondary Outcome Measures

    1. Measurement of BMI [6 months]

      BMI between different patient types

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 45 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Premenopausal women with PCOS (Rotterdam criteria) attending the endocrine clinic, aged between 18-45 years
    Exclusion Criteria:
    • There is a clear exclusion criteria under the Rotterdam criteria; age <18 years or >45 years; oral contraceptive use within 3 months prior to recruitment, diabetes mellitus & pregnancy

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 St George's Hospital Trust London United Kingdom SW17 0RE

    Sponsors and Collaborators

    • St George's, University of London
    • SPD Development Company Limited

    Investigators

    • Principal Investigator: Suman Rice, PhD, St George's, University of London

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    St George's, University of London
    ClinicalTrials.gov Identifier:
    NCT03652987
    Other Study ID Numbers:
    • 18.0049
    First Posted:
    Aug 31, 2018
    Last Update Posted:
    May 25, 2021
    Last Verified:
    Jun 1, 2020
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by St George's, University of London
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 25, 2021